

May 2015 | Issue Brief

# **Corruption and Global Health: Summary of a Policy Roundtable**

Josh Michaud, Jennifer Kates, and Stephanie Oum

# **INTRODUCTION**

Global health efforts, like all development programs, are vulnerable to corruption. Corrupt acts, where and when they occur, can divert global health funding from its intended purpose and dilute the impact of programs aimed at preventing disease, treating illness, and saving lives. Corruption, though, has been hard to define and even harder to comprehensively track and understand. While most recognize that corruption exists and can negatively impact development programs, including those of the U.S. government (USG), there are ongoing debates about the scope and impact of corruption and whether and how global health programs should address it.

On one hand, some view corruption as a very important – if not the *most important* – issue in many countries today, and leaders and the public alike often point to corruption as a major barrier for development and global health programs. World Bank President Jim Kim has called corruption "public enemy number one,"<sup>1</sup> and U.K. Prime Minister David Cameron stated that corruption is the "archenemy of democracy and development."<sup>2</sup> Members of the U.S. Congress have also expressed concerns about corruption and its effects on U.S. global health and foreign aid programs.<sup>3,4</sup> The public in developing countries often place corruption at the top of their list of concerns, <sup>5,6</sup> and the public in donor countries such as the U.S. and U.K. express worry about corruption and its ability to undermine global health and foreign assistance.<sup>7</sup> For example, in a recent Kaiser Family Foundation *Survey of Americans on the U.S. Role in Global Health*, 83% of the U.S. public considered corruption to be a major barrier to effective global health programs, and 47% considered it the *single-most important* barrier.<sup>8</sup>

In contrast, others consider corruption to be worrisome, but do not believe it rises to the level of a central policy concern for global health and development efforts. Harvard Professor and Partners in Health co-founder Paul Farmer has written that even though some people believe poor countries are too corrupt for foreign assistance programs to work effectively, "the numbers regarding aid... tell a reassuring story."<sup>9</sup> The Bill & Melinda Gates Foundation also views corruption as something donors and others need to be vigilant about, but warns against placing too much emphasis on it. Writing in his Foundation's *2013 Annual Letter*, Bill Gates stated "we need to root out fraud and squeeze more out of every dollar... but we should also remember the relative size of the problem."<sup>10</sup>

These differing points of view hint at the spectrum of opinions that exist regarding the extent of corruption and the implications it has for global health and development programs, including those of the USG. In light of these ongoing uncertainties and debates about corruption and global health, the Kaiser Family Foundation

convened a roundtable of experts from the U.S. government, academia, multilateral institutions, NGOs, think tanks, and other organizations for a policy discussion on this topic.

The roundtable discussion focused on the following questions:

- What is the magnitude of the problem corruption represents for global health? What is corruption and how does it manifest in global health? What research methods, tools, and approaches can help us understand the problem better?
- Are current anti-corruption policies and programs adequate? How do U.S. government global health programs monitor and address corruption? Should more be done? What are current best practices?
- How can we communicate more effectively about corruption to policymakers and the **public?** What is the right balance between transparency about corruption and risking unnecessary and damaging backlash?

This document summarizes the key themes that emerged from the roundtable discussion. Discussion points are supplemented with examples and information drawn from background materials and published literature that were referenced by participants. A list of related materials and resources is provided in the Appendix.

# **ROUNDTABLE SUMMARY**

# QUESTION 1: WHAT IS THE MAGNITUDE OF THE PROBLEM CORRUPTION REPRESENTS FOR GLOBAL HEALTH?

A key question for roundtable participants was: what is the best estimate for how much loss is incurred through corruption in the health sector? Participants felt this question is exceedingly difficult to answer, primarily because measuring losses to corruption is a challenge. First, there is no standard definition of corruption. Corrupt activities are also hard to identify, track, and verify in many cases. In addition, current measurement tools and approaches are often applied in only a limited way, and no single tool or approach can give a comprehensive assessment of monetary losses from corruption or the ultimate impact that corruption has on population health. Therefore, participants agreed it is a nearly impossible task to accurately estimate losses from corruption in the global health sector overall.

#### Difficulties in Defining and Identifying Corruption

According to participants, there is no widely accepted standard definition of corruption, but many found Transparency International's description helpful, albeit very general: "*the abuse of entrusted power for private gain.*"<sup>11</sup> The United Nations Convention against Corruption (UNCAC), the most prominent international treaty and policy statement on corruption and combatting it, does not define corruption per se, but instead describes various types of corruption including: bribery, embezzlement, theft, fraud, and others.<sup>12</sup> Box 1 provides a list and short definitions for commonly used categories of corruption.

#### Box 1. Types of Corruption

*Bribery*: offering, promising, giving, accepting or soliciting of an advantage as an inducement for action that is illegal, unethical or a breach of trust.

*Collusion*: A secret agreement between parties to conspire to commit actions aimed to deceive or commit fraud with the objective of illicit financial gain.

*Extortion*: utilizing, directly or indirectly, one's access to a position of power to demand unmerited cooperation or compensation as a result of coercive threats.

*Embezzlement*: Act of dishonestly and illegally appropriating, using or trafficking the funds and goods that office holders have been entrusted with, for personal enrichment or gain.

*Fraud*: Act of an office holder intentionally deceiving someone in order to gain an unfair or illegal advantage (financial, political, or otherwise).

*Favoritism/nepotism*: favorable treatment of friends and associates in the distribution of resources and positions, regardless of their objective qualifications and merit.

*"Petty"/administrative*: lower-level corruption often involving bureaucrats who control access to public services, who demand bribes before performing public duties.

*"Grand"/political*: major embezzlement or exchange of resources such as bribes for advantages among elites at high levels of government and private industry, often associated with budgeting, position buying, investments, and large infrastructure/construction projects.

*State capture*: when laws, policies or state institutions meant to benefit the public good have been "captured" through bribes or other means by individuals in order to foster political or personal economic interests.

Source: Adapted from Hussmann K (2011). Addressing corruption in the health sector. U4 Anti-Corruption Resource Centre.

Participants stated that corrupt acts are often hidden from view, making them difficult to track, study, and verify. They pointed out that the line between corruption and inefficiency is often blurry and it can sometimes be difficult to tell the difference between corrupt acts and poor management. Another difficulty is that there are cultural and sociological differences regarding what is corrupt vs. acceptable practice. What is considered "corruption" can vary from country to country and sector to sector. While some acts – such as outright fraudulent misdirection of funds intended for health services – are likely to be almost universally considered corrupt, in other cases – such as when gifts and money are given to health providers – it can be difficult to agree on whether a specific act constitutes corruption or not.

Therefore, participants agreed that because it is often so difficult to find and prove corruption, it remains a serious challenge to measure and quantify it. In fact, many felt it would not be worth the effort, and might not

even be possible, to comprehensively evaluate the overall impact of corruption on global health due to these limitations.

### Measurement and Evaluation Tools Can Shed Light in Specific Areas

While recognizing the difficulty of estimating the total impact of corruption on the health sector as a whole, participants did state that measurement and evaluation of corruption within specific components of health systems or focused on specific health programs or activities can be helpful to understand where and how corruption occurs. In this context, participants mentioned a number of tools and approaches.

Participants stated that some of the most commonly referenced corruption measures are based on surveys asking people about their opinions and experiences with corruption, such as Transparency International's Corruption Perception Index or AfroBarometer polls.<sup>13,14</sup> For example, opinion surveys of the public in 7 countries performed between 2001 and 2006 found the percent of the public who believed the health system in their country was "corrupt" or "very corrupt" ranged from 20% in Indonesia to 56% in Sierra Leone.<sup>15</sup> While estimates such as these can point to general levels of concern about corruption in the health sector, participants agreed that such measures are problematic because perceptions and opinions about corruption can differ from the true prevalence of corrupt practices.

Other approaches to identifying and measuring corruption referenced by participants included: studies of personal experiences with corruption by individuals, households, health workers, and government officials (e.g. how much/how often have they have been party to paying or requesting bribes or other corrupt acts), and public expenditure tracking survey (PETS) for health, which can be used to follow how public funding flows from the point of central disbursement to how it is used to pay for health services in states, counties, and other localities. One approach used by donors is the portfolio review, in which a sample of grants is investigated by an Inspector General or other neutral office. The World Bank, the Global Fund to Fight AIDS, TB and Malaria, and USAID have all used portfolio reviews as a way to identify fraud and other instances of waste and/or corruption, and measure losses.<sup>16</sup>

While each of these approaches can shed some light on specific areas and instances of corruption, participants felt that none in isolation can fully determine the extent of and losses due to corruption.

# Need for Continued, and in Some Cases, Expanded Measurement by Donors

Though participants felt pursuing a broad, overall estimate of losses to corruption in global health presented many difficulties they did agree that corruption in the health sector can be a serious problem, and that global health programs could do more to try to measure and understand it. Participants stated that just because corruption cannot be accurately measured at a global level does not mean such acts do not occur or that they have little impact on global health programs. To give some indication of how corruption manifests itself in health systems, participants pointed to a number of published studies that highlight the kinds of corrupt activities that can take place. Table 1 provides a selection of data points from published studies on corruption in different components of the health systems of low- and middle-income countries.

Participants felt current donor approaches to assessing the risks and impacts of corruption are often inadequate. Typically, donors such as the U.S. will audit programs in reaction to a complaint or some prior

evidence of fraud or abuse. They said it is much rarer to see donors engage in proactive, preventative investigations focusing on a randomly selected sample of grants even though this approach could provide a more robust estimate of corruption and waste. Such a randomized approach has been used for some U.S. domestic health programs such as Medicare to track so-called "improper payments" (includes fraud and abuse as well as other categories of misuse of funds), but has not been widely utilized for assessing foreign assistance or global health portfolios.

Table 1: Selected Estimates of Corruption in Health from Published Studies	
Year(s)	Corruption Estimate
1999	68-77% of health system user fees misappropriated or pocketed in Uganda <sup>17</sup>
2000	21% of hospital procurements estimated diverted due to corruption in Ghana <sup>18</sup>
2000-2006	In a study of 6 countries, the percent of patients surveyed reporting having to make informal payments for service ranged from 4% in Benin to 35% in Sierra Leone <sup>19</sup>
2001-2006	Opinion surveys of the public in 7 countries found the percent of the public who believed the health system was "corrupt" or "very corrupt" ranged from 20% in Indonesia to 56% in Sierra Leone <sup>19</sup>
2001-2006	Surveys in 6 countries found the percent of health worker absenteeism ranged from 6% in Cameroon to 25% in Peru to 40% in India <sup>19</sup>
2003	In Thailand, a reported 8.5% of medicines were considered sub-standard <sup>20</sup>
2005	20% of public officials in Guinea reported job purchasing in the health system is "common" or "very common" <sup>19</sup>
2011	After reviewing grant portfolios in 25 of 145 recipient countries, the Global Fund's Office of the Inspector General reports 0.8% of disbursed grants to those countries (\$39m of \$4.8b total) was lost to fraud <sup>21</sup>
2012	Across seven countries in Asia, 36% of antimalarial drugs being sold were falsified; in 21 countries in sub- Saharan Africa, 20% were falsified <sup>22</sup>
2013	An internal review conducted by Gavi, the Vaccine Alliance (a multilateral financing mechanism for immunizations in developing countries) found that 31% of one grant (\$523m out of \$1.685B) to Sierra Leone had been misappropriated <sup>23</sup>
2013	The percent of patients who reported paying a bribe to obtain health services in 8 countries in central and eastern Europe ranged from 4% in Croatia to 32% in Bosnia-Herzegovina <sup>24</sup>

Further, participants felt that more studies linking corruption in the health sector and the resulting negative impacts on population health would be helpful. A few studies on this topic have been published,<sup>25</sup> but participants felt that more evidence linking corrupt practices with real human health impacts could be an important way to understand and highlight the human costs of corrupt acts.

# **QUESTION 2: ARE CURRENT ANTI- CORRUPTION EFFORTS ADEQUATE?**

According to participants, anti-corruption efforts can take many forms that can range from broad governance and rule of law programs to more sector-specific approaches. Global health-specific anti-corruption programs are not common, especially within the U.S. government's global health portfolio, but participants stated that successful examples of such efforts do exist and can be instructive. Overall, participants felt more could be done by donors on health sector-specific anti-corruption policies and programs, especially in light of a number of

<sup>\*</sup> According to estimates from U.S. Government Accountability Office, \$60 billion in "improper payments" were made through Medicare in 2014, representing over 10% of the \$492 billion spent on Medicare that year. An unknown portion of the \$50 billion represents actual fraud. Source: <u>http://www.gao.gov/highrisk/medicare\_program/why\_did\_study#t=0</u>.

factors that could potentially contribute to greater corruption risks within global health, such as an increasing emphasis on "local ownership" of health programs and the growing need for health programs to work in fragile, conflict and post-conflict states where disease burden is concentrated but governance can be weak.

#### Approaches to Anti- Corruption in Health

Participants discussed a variety of anti-corruption efforts. Some are broad-based programs that focus on improving the judicial system and supporting the rule of law or building general governance and leadership capacity of a country. Other efforts target certain areas or sectors, such as programs that address specific components of the health system. Some of the types of policies and programs in the health sector participants discussed are listed in Box 2. Participants reported that the two types of efforts – broad and sector-specific – remain isolated for the most part. They recommended fostering a combined approach that utilizes both broad and targeted anti-corruption efforts together in a coordinated fashion.

#### Box 2. Examples of Anti- Corruption Policies and Programs

Robust internal audit /portfolio review

Collecting baseline data (absenteeism, informal payments, stockouts) to show that policy changes and interventions work

Designing and implementing complaint mechanisms

Supporting administrative law

Civil society watchdog organizations & social audit; health boards

Insurance fraud control (data mining for detection, transparency on entitlements, sanctions)

Innovative financing approaches such as results-based aid and performance-based financing

Quality improvement/clinical audit

Health management systems strengthening & supervision

Coordination with efforts to promote better governance in other sectors

Sources: adapted from Vian T, Savedoff W, and Mathisen H. (2010). Anticorruption in the Health Sector. Kumarian Press; and Hussmann K (2011). Addressing corruption in the health sector. U4 Anti-corruption Resource Centre.

Participants also discussed ways donors could do more to reduce the risks of corruption through changes in their practices. For example, donors can diagnose and track potential waste and corruption through more regular use of portfolio reviews (described above) to examine recipients of global health grants and the trail of funding. Findings from such reviews in the past have led to further investigations and prosecution of corruption. Losses could be recouped and these efforts could have a preventative effect against further infractions. Participants also discussed utilizing innovative financing approaches such as results-based aid

and/or performance-based financing.<sup>26</sup> Participants felt that by using such innovative approaches – delivering aid according to outcomes rather than inputs – donors can reduce the risk for abuse and fraud.

Other approaches discussed by participants involve working with country partners to reduce corruption risks in country health systems. For instance, donors could support targeted anti-corruption efforts to improve governance and oversight of health programs and better identify and minimize loss from corruption. Examples of such approaches include: collecting and sharing baseline data on corruption, instituting quality improvement, automated monitoring and complaint mechanisms, and involving civil society through watchdog groups or community health boards to promote better oversight and accountability. Participants pointed to several examples of successful health system anti-corruption efforts, some which are listed in Table 2.

Participants identified some common characteristics of successful anti-corruption programs for health. For example, programs can be more successful if they consist of more than one intervention because singular approaches may only shift risk; a complementary set of policy changes is typically a more effective approach.<sup>27</sup> Participants also stated that it is often invaluable for anti-corruption efforts to take place where there is committed leadership among the implementers and partners because it is difficult to impose successful anti-corruption interventions externally. Participants felt that successful programs reflect input and participation from patients, clients, and other affected members of the health system and communities, as this increases the transparency of health programs and generates more accountability among leaders and policymakers.

#### Table 2: Selected Examples of Successful Anti- Corruption Interventions in the Health Sector

Description of Anti-Corruption Program and Impact

User fee revenue theft in provincial referral hospitals in Kenya was virtually eliminated through installation of networked electronic cash registers<sup>28</sup>

A multi-pronged strategy including overhauling the government drug regulator, stepped up enforcement and a public information campaign led to an 80% reduction in fake drugs in the Nigerian market in 2004<sup>19</sup>

Health Public Expenditure Tracking Surveys (PETS) in Chad and Ghana identified funding flows from central to regional/district level represented the largest risk of leakages, allowing for stricter oversight in areas of weakness and subsequent reduced losses<sup>19</sup>

Citizen participation in health boards in Bolivia led to significant decreases in illegal overpayment for drugs and supplies, for example a 40% reduction in price for intravenous solution<sup>29</sup>

Pay for performance mechanisms linking health worker bonuses to facility performance increased quality, boosted utilization, and reduced the incidence of informal payments in Cambodia<sup>30</sup>

Revised rules and transparency about hospital fees, sharing earned revenue with staff, and other rewards discouraged informal payments in Georgia<sup>31</sup>

Overall, participants felt anti-corruption efforts such as these could be effective for global health programs given additional, sustained support from donors.

#### U.S. Government Anti- corruption Efforts and Global Health

Participants indicated that U.S. anti-corruption efforts through foreign assistance tend to concentrate on broader, cross-sectoral approaches to combating corruption. For example, most USAID assistance for anti-corruption is targeted at rule of law, democratization, and governance programs rather than sector-specific programs in health or other areas.<sup>32</sup>

Participants did note that U.S. global health assistance is reviewed on a regular basis for fraud, waste, and abuse, typically through audits led by the Office of the Inspector General (OIG) in each of the departments and agencies responsible. For example, the legislation for PEPFAR (the President's Emergency Plan for AIDS Relief), requires that the departments overseeing the HIV/AIDS, TB, and malaria programs authorized through that legislation submit a coordinated audit plan, and share with Congress the results of those audits. These audits are meant to determine whether funded projects meet stated goals and objectives, though in the course of performing them, auditors may encounter instances of waste, fraud, and abuse. Additional investigations of specific acts of corruption can be triggered by complaints or whistleblowers, though results from such investigations are typically not made public.

Even though participants felt audit and oversight of this kind can be helpful, some expressed concern that the current U.S. approach is ad-hoc and does not allow for a robust assessment of U.S. funding lost to corruption, waste, and/or fraud. A more informative approach, according to participants, would be to perform audits of a randomly selected subset of all grants/projects. This would provide for a more comprehensive picture of losses and point to areas of concern more effectively.<sup>33</sup>

Participants felt there are other changes in approach and practice that the U.S. could implement to reduce corruption risks. For one, the U.S., with its annual appropriation process, can try to avoid the situation in which there is pressure to get funds "out the door" at the end of the fiscal year, a practice that can lead to less oversight and, therefore, higher risk of misappropriation or abuse by the recipients of these funds. In addition, donors can ensure country strategic and operational plans explicitly address anti-corruption goals, as they relate to the health sector specifically.<sup>34</sup> Currently, such plans only rarely incorporate or even mention anti-corruption objectives. Further, participants felt the U.S. should consider adopting results-based and performance-based approaches wherever possible, which can help reduce corruption by spending on outcomes as opposed to inputs.<sup>35</sup>

Participants discussed key trends in global health assistance that could have implications for anti-corruption efforts of the U.S. and other donors. The first was the growing emphasis toward shifting USG global health financing away from U.S.-based non-governmental organizations (NGOs) and toward "local ownership" and local organizations.<sup>36</sup> Some participants argued that making such a shift increases the risk of corruption because there is potentially less accountability and fewer controls in local organizations as compared to U.S.-based NGOs. Others saw shifting resources in this manner as a way to foster sustainable capacity in countries to combat corruption because, by supporting local organizations, donors can help community stakeholders organize and hold governments accountable.<sup>37</sup> Overall, participants felt that as the emphasis on local partnerships grows, U.S. programs must ensure that sufficient safeguards are in place to minimize any risks to losses from corruption.

Another tension discussed by the roundtable participants was balancing burden of disease and governance considerations. Many of the countries where corruption risks are highest – those with weak institutions and those facing conflict and post-conflict situations – often face the greatest burdens of disease. Participants debated whether the U.S. should focus assistance where the need is greatest but governance may be weakest, or whether it was better to direct investments to countries with a track record of good governance. No simple solutions to the conundrum were identified, but participants felt it was important for the U.S. and other donors

to consider this tension when developing policy. Participants also stated the U.S. needs to be sensitive to "backsliding" in governance standards as a result of governmental or societal change, which highlights the need for sustained anti-corruption efforts over time.

# **QUESTION 3: HOW CAN WE COMMUNICATE ABOUT CORRUPTION MORE EFFECTIVELY?**

Participants agreed that communicating about corruption to the public and policymakers presents a number of challenges. For one, some level of corruption is likely a part of any large-scale global health program, but can be difficult to discuss openly because the public and policymakers have proved to be extremely sensitive about the topic. Many in the public already have a strong belief that corruption represents an enormous drain on foreign assistance programs even though available evidence indicates that losses from corruption do not match perceptions, according to participants. For example, in a 2013 KFF survey, Americans reported on average they thought about half of every dollar the U.S. spends on global health was lost to corruption, and that only 23 cents of every dollar spent actually reaches the people who really need it.<sup>36</sup> Roundtable participants felt such estimates represent a tendency of the public to believe the problem is worse than it really is, and can lead to misplaced doubts about the effectiveness of global health assistance and foreign aid in general.

Participants were concerned that entrenched public beliefs about the prevalence and impact of corruption can lead to donors to being overly sensitive about perceptions of corruption occurring in their programs. As was asked during the discussion: how much is the fear of a corruption-fueled headline limiting agencies' willingness to confront corruption? Participants did recognize that donors sometimes find themselves in difficult situations after corrupt acts are identified, especially when the media sensationalize a story. Participants noted a well-known example of this from 2011, when an Associated Press article on corruption within some Global Fund grants led several Global Fund donors to threaten withholding support even though the corrupt acts were discovered and reported by the Global Fund itself, and the actual amount lost to corruption was much less than was insinuated in the article. As was evidenced by the Global Fund experience, there can be a disproportionate backlash for agencies and organizations when corruption is identified and publicized. Participants worried that this interplay between public perceptions and transparency about corruption has fostered an environment where leaders and program managers commit to "zero tolerance for corruption" policies even though such goals are probably unrealistic. In the current environment, participants worried that donors often wish to avoid even talking about the corruption that is an inevitable part of any health system, or even worse, may turn a blind eye or ignore the problem for fear of potential repercussions.

According to participants, shifting the pervasive negative public opinions in the U.S. and other donor countries about the extent and impact of corruption in global health assistance is a difficult and long-term task. Barring a sea change in public opinion, participants felt that a more proactive, preventative approach to communication about corruption is a better option than not discussing or ignoring it. Participants discussed preliminary research on public messaging about corruption and its impact on public opinion, which indicates that the stigma associated with discussing corruption can be ameliorated by focusing on more active, positive messages about what is being done to combat it rather than waiting until corruption is reported before acting. As an early step, participants said donors can do more to emphasize and highlight successful anti-corruption interventions, as these can lead the public and political leadership to understand that steps are being taken to address the issue.

Still, there was recognition among participants that global health programs may face a "catch-22" situation with complicated and sometimes perverse incentives. If donors and country governments do a better job at identifying corruption, the result may actually be a decline in willingness to finance global health programs in those areas or with those partners, even though the risk of loss to corruption may have been reduced. Ultimately, more needs to be understood about the relationship between implementing greater transparency and accountability interventions and the impact on corruption and public perception. Pilot studies have begun to look at such issues but results are not yet available.<sup>39</sup> Participants felt this is an area of study that donors could do more to support given the potential lessons that could be drawn.

# **CONCLUSIONS AND NEXT STEPS**

The roundtable discussion was wide-ranging, covering many aspects of corruption and global health. Participants were in agreement that it is not really possible to know what percentage of financing for global health is lost to corruption, given data limitations and the challenge of measuring corrupt activities. Even so, participants felt corruption does occur and can dilute the impact of global health financing, and current donor approaches to assessing risks and impacts of corruption are often inadequate. Current anti-corruption programs, particularly those funded by U.S. government agencies, tend to focus on broader reform of the justice system, rule of law and governance. Expanding health sector specific anti-corruption efforts could complement these important efforts especially given that there have been some examples of successful anticorruption programs in health. On the question about communicating about corruption, participants recognized the potential difficulties in being more transparent and direct about corruption risks and efforts to reduce them in the context of global health programs, but also felt that a more proactive approach may be a better strategy than trying to avoid talking about the problem for fear of backlash.

Although participants felt that solutions will differ by location and circumstances, and no "one-size fits all" approach can work everywhere, there are a number of concrete steps that donors, such as the U.S., could take to better address corruption in global health. Some of these steps include:

- Invest in research on further measuring and understanding corruption in the health sector;
- Dedicate more resources to investigate and understand the true risks of corruption through such tools as portfolio review applied to a broader, random sample of grants and sector-specific studies in coordination with in-country partners;
- Incorporate explicit anti-corruption policies and interventions into U.S. and partners' global health strategic and operational plans;
- Link global health programs with broader rule of law and governance reform efforts whenever possible;
- Implement and expand anti-corruption interventions in health, building upon already proven models, which should be adapted to local circumstances;
- Promote anti-corruption efforts and highlight successes.

Ultimately, participants felt that it is important for the U.S. and other donors to dedicate more funding and time to understanding and combatting corruption in global health. While they felt the problem of corruption in health may not rise to the level of concern expressed by some policymakers and by the public at large, it is still an issue that needs to be confronted more effectively going forward.

# **RESOURCE LIST**

#### General Background/Overview/Theory

Campos, J. E., and Pradhan, S. (2007). The many faces of corruption: tracking vulnerabilities at the sector level. World Bank.

Savedoff, W. and Hussmann, K. (2006). Why are health systems prone to corruption? Transparency International Global Corruption Report 2006.

UNDP (2011). Fighting Corruption in the Health Sector. Methods, Tools, and Good Practices. <u>http://www.undp.org/content/undp/en/home/librarypage/democratic-governance/anti-corruption/fighting\_corruptioninthehealthsector.html</u>.

Vian, T. (2005). The Sectoral Dimensions of Corruption: Health Care. Fighting Corruption in Developing Countries: Strategies and Analysis. Edited by Bertram I. Spector. 43-63. Bloomfield, CT: Kumarian Press.

Vian, T. (2006). Corruption in Hospital Administration. Global Corruption Report 2006. Edited by Transparency International. 48-61. London: Pluto Press.

Vian, T. (2008). Corruption and the Consequences for Public Health. International Encyclopedia of Public Health. Vol 2. 26-33. San Diego, CA: Academic Press.

Vian, T. (2008). Review of corruption in the health sector: theory, methods, and interventions. Health Policy and Planning 23 (2): 83-94. doi: 10.1093/heapol/czm048

#### Estimates of corruption in the health sector and links to health impacts

Amnesty International (2009). Giving Live, Risking Death. <u>http://www.amnesty.org.nz/files/afr600012009en.pdf</u>.

Azfar, O. and Gurgur, T. (2008). Does corruption affect health outcomes in the Philippines? *Economics of Governance* July 2008, Volume 9, Issue 3, pp 197-244.

Gee J, Button M. (2014). The financial cost of healthcare fraud. <u>https://fullfact.org/wp-content/uploads/2014/03/The-Financial-Cost-of-Healthcare-Fraud-Report-2014-11.3.14a.pdf</u>.

Hanf M, et al. (2011). Corruption Kills: Estimating the Global Impact of Corruption on Children Deaths. PLoS ONE 6(11): e26990. doi:10.1371/journal.pone.0026990

International Monetary Fund (2000). Corruption and the provision of health care and education services. <u>http://www.imf.org/external/pubs/ft/wp/2000/wp00116.pdf</u>

Kohler JC. (2011). Mapping of Good Practices of Anti-Corruption Interventions in the Health Sector. Prepared for the UNDP Democratic Governance Group, New York.

Lewis M. (2000). Who is paying for health care in Eastern Europe and Central Asia? World Bank Publications.

Lewis M. (2006). Governance and corruption in public health care systems. Center for Global Development working paper, (78).

Lin RT, et al. (2014). Governance matters: an ecological association between governance and child mortality. *Int Health*. 6(3):249-57. doi: 10.1093/inthealth/ihu018. Epub 2014.

Vian T, et al. (2013). Perceptions of per diems in the health sector: Evidence and implications. *Health Policy & Planning*. 28(3):237-246.

Witvliet MI, et al. (2013). Sick regimes and sick people: a multilevel investigation of the population health consequences of perceived national corruption. *Tropical Medicine and International Health*. 18(10):1240–1247.

#### **Country/region specific studies**

Avelino G, Barberia LG, Biderman C (2013). Governance in managing public health resources in Brazilian municipalities. *Health policy and planning.* 2014 Sep;29(6):694-702. doi: 10.1093/heapol/czt003. Epub 2013 Feb 14.

Burak LJ, Vian T (2007). Examining and predicting under-the-table payments for healthcare in Albania: An application of the theory of planned behavior. Journal of Applied Social Psychology. 37(5): 1060-1076.

Ghosh A, Ahmad S. (1996). Plague in Surat: Crisis in Urban Governance. New Delhi: Concept Publications.

Ha T, et al (2011). Towards a Transparent and Quality Healthcare System: A Qualitative Study on the Causes, Perceptions and Impact of Informal Payments in Health Services in Vietnam.

http://archive.transparency.org/regional pages/asia pacific/transparency international in vietnam/publications/research and su rveys.

Schulz-Herzenberg C (2007). A lethal cocktail. Institute for Security Studies. Transparency International. Zimbabwe.

Vian T, et al (2012). Confronting corruption in the health sector in Vietnam: Patterns and prospects. *Public Administration and Development* 32: 49-63.

Vian T (2013). Complaint mechanisms in health organizations. U4 Brief. Bergen, Norway: U4 Anti-corruption Resource Centre. <u>http://www.u4.no/publications/complaints-mechanisms-in-health-organizations/</u>

Vian T (2013). Implementing a Transparency and Accountability Policy to reduce corruption: the GAVI Alliance in Cameroon. U4 Brief. Bergen, Norway: U4 Anti-corruption Resource Centre. <u>http://www.u4.no/publications/implementing-a-transparency-and-accountability-policy-to-reduce-corruption-the-gavi-alliance-in-cameroon/.</u>

Vian T (2014). Corruption risk assessment in the health sector in Kosovo. UNDP: Pristina, Kosovo.

Vian T, Bicknell WJ (2013). Good governance and budget reform in Lesotho Public Hospitals: performance, root causes and reality. *Health Policy and Planning* 2014 Sep;29(6):673-84. doi: 10.1093/heapol/czs121. Epub 2013 Jan 4.

Vian T, Burak LJ (2006). Beliefs about informal payments in Albania. Health Policy and Planning 21 (5): 392-401.

Vian T, Feeley FG (2014). Framework for addressing out-of-pocket and informal payments for health services in Moldova. Chisinau, Moldova: WHO. <u>http://www.euro.who.int/en/countries/republic-of-moldova/publications2/health-policy-paper-series-no.-16-framework-for-addressing-out-of-pocket-and-informal-payments-for-health-services-in-the-republic-of-moldova-2014.</u>

Vian T, et al (2006). Informal Payments in Government Health Facilities in Albania: Results of a Qualitative Study. *Social Science and Medicine* 62: 877-887.

#### Focus on the Pharmaceutical Sector

Attaran A, et al (2012). How to achieve international action on falsified and substandard medicines. BMJ, 345.

Baghdadi-Sabeti G, et al (2009). Measuring transparency in the public pharmaceutical sector: Assessment instrument. WHO/EMP/MAR/2009.4. Geneva: World Health Organization. http://www.who.int/medicines/areas/policy/goodgovernance/AssessmentInstrumentMeastranspENG.PDF.

Baghdadi-Sabeti G, Serhan F (2010). WHO Good Governance for Medicines programme: an innovative approach to prevent corruption in the pharmaceutical sector. Compilation of country case studies and best practices. World Health Organization. <u>http://apps.who.int/medicinedocs/en/d/Js17550en/</u>.

Cohen JC, et al (2007). Corruption and pharmaceuticals: Strengthening good governance to improve access. *The Many Faces of Corruption: Tracking Vulnerabilities at the Sector Level.* Washington DC: World Bank.

Kohler JC, Baghdadi-Sabeti G (2011). The World Medicines Situation 2011. World Health Organization.http://www.who.int/medicines/areas/policy/world\_medicines\_situation/WMS\_ch20\_wGoodGov.pdf.

Kohler JC, et al (2014). Why the MDGs need good governance in pharmaceutical systems to promote global health. *BMC Public Health* 14(1):63.

Morris J, Stevens P (2006). Counterfeit medicines in less developed countries. London: International Policy Network, May, 3, 6. <u>http://counterfeiting.unicri.it/docs/Ctf%20medicines%20in%20less%20developed%20countries.pdf.</u>

Waning B, Vian T (2008). Transparency and accountability in an electronic era: the case of pharmaceutical procurements. U4 Brief, 2008(10). http://www.cmi.no/publications/publication/?3030=transparency-and-accountability-in-an-electronic.

World Bank (2002). Improving transparency in pharmaceutical systems: strengthening critical decision points against corruption: a case study of Costa Rica.

https://openknowledge.worldbank.org/bitstream/handle/10986/20426/905920WP0Box3800wb0paper0pharma2002.pdf

World Health Organization. (2014). Good Governance in the Pharmaceutical Sector: Report of a World Health Organization Technical Working Group. <u>http://www.who.int/medicines/areas/governance/ggm\_tunis\_meeting\_report.pdf</u>

Vian T (2006). Preventing drug diversion through supply chain management: U4 Brief. No. 4. U4 Anti-Corruption Resource Center. http://www.cmi.no/publications/publication/?2569=anti-corruption-in-the-health-sector

#### Anti- corruption methods/approaches/tools/evaluations

Brinkerhoff DW (2010). Unpacking the concept of political will to confront corruption. U4 Brief. No. 1. U4 Anti-Corruption Resource Center. <u>http://www.u4.no/publications/unpacking-the-concept-of-political-will-to-confront-corruption/</u>

Ciccone DK, et al. (2014). Linking governance mechanisms to health outcomes: a review of the literature in low- and middle-income countries. *Social Science and Medicine* 117:86-95.

Kohler JC, Makady A (2013). Harnessing global health diplomacy to curb corruption in health. J Health Dipl, 1(1), 1-14.

Mackey TK, Liang BA. (2012). Combating healthcare corruption and fraud with improved global health governance. *BMC International Health and Human Rights* 12(1):23.

Rashidian A, et al (2012). No Evidence of the Effect of Interventions to Combat Health Care Fraud and Abuse: A Systematic Review of Literature. *PLoS ONE* 7(8): e41988. doi:10.1371/journal.pone.0041988.

USAID (2009). Anti-corruption assessment handbook. http://pdf.usaid.gov/pdf\_docs/pnadp270.pdf.

USAID (2014). Analysis of USAID Anticorruption Programming Worldwide (2007-2013). <u>http://www.usaid.gov/sites/default/files/documents/1866/AnalysisUSAIDAnticorruptionProgrammingWorldwideFinalReport2007-2013.pdf</u>.

Vian T (2006). Reducing vulnerabilities to corruption in user fee systems: U4 Brief. No. 3. U4 Anti-Corruption Resource Center. http://www.cmi.no/publications/publication/?2568=anti-corruption-in-the-health-sector

Vian T (2008). Transparency in health programs. U4 Brief, No. 9. U4 Anti-Corruption Resource Center. <u>http://www.cmi.no/publications/publication/?3029=transparency-in-health-programs</u>

Vian T (2009). Approaches to teaching and learning about corruption in the health sector. U4 Brief, No. 30. U4 Anti-Corruption Resource Center. <u>http://www.cmi.no/publications/publication/?3531=approaches-to-teaching-and-learning-about</u>

Vian T (2009). Benefits and Drawbacks of Per Diems: Do Allowances Distort Good Governance in the Health Sector?U4 Brief, No. 29. U4 Anti-Corruption Resource Center. <u>http://www.cmi.no/publications/publication/?3523=benefits-and-drawbacks-of-per-diems</u>

Vian T (2012). Exploring the construction of transparency: An analysis of health managers' narratives. Global Health Governance. Vol V. No. 2.

Vian T, Collins D. (2006). Using financial performance indicators to promote accountability and transparency in health systems: U4 Brief. No. 1. U4 Anti-Corruption Resource Center. <u>http://www.cmi.no/publications/publication/?3524=using-financial-performance-indicators-to-promote</u>

Vian T, et al (2010). Anticorruption in the Health Sector: Strategies for Transparency and Accountability. Kumarian Press.

Vian T, et al (2012). Perceptions of per diems in the health sector: evidence and implications. *Health Policy and Planning* 28(3):237-46. doi: 10.1093/heapol/czs056. Epub 2012 Jun 8. <u>http://heapol.oxfordjournals.org/content/early/2012/06/08/heapol.czs056.short</u>

#### Other

Musau S, Vian, T (2008). Fraud in hospitals. U4 Brief, No. 8. U4 Anti-Corruption Resource Center. <u>http://www.cmi.no/publications/file/3028-fraud-in-hospitals.pdf</u>

Semrau K, et al (2008). Embezzlement of Donor Funding in Health Projects. U4 Brief, No. 11. U4 Anti-Corruption Resource Center. http://www.cmi.no/publications/publication/?3031=embezzlement-of-donor-funding-in-health-projects

Soreide T et al (2014). Consequences of Corruption at the Sectoral Level and Implications for Economic Development (the G20 Paper on Corruption in Sectors). Prepared for the G20 Anti-Corruption Working Group in Rome 9-11 June 2014. Paris: OECD.

The Global Anticorruption Blog: <u>http://globalanticorruptionblog.com/</u>

U4 Anticorruption Resource Centre: http://www.u4.no/

World Bank Integrity Vice Presidency Website: http://go.worldbank.org/1ZEK9VGAR0

World Health Organization. Good Governance for Medicines (GGM) Website. http://www.who.int/medicines/areas/governance/en/

# **ENDNOTES**

<sup>1</sup> "World Bank President Calls Corruption 'Public Enemy No. 1". Reuters December 19, 2013. http://www.reuters.com/article/2013/12/19/us-worldbank-corruption-idUSBRE9BI11P20131219.

<sup>2</sup> Cameron D. "The Corruption Cure: Transparency, Taxes, Trade." Wall Street Journal June 4, 2014. http://www.wsj.com/articles/david-cameron-the-corruption-curetransparency-taxes-trade-1401913005.

<sup>3</sup> Dunning C (2011). "U.S. Foreign Assistance and Corruption: It's All Relative". Center for Global Development Blog Post. <u>http://www.cgdev.org/blog/us-foreign-assistance-and-corruption-it%E2%80%99s-all-relative</u>.

<sup>4</sup> House Committee on Oversight and Government Reform. "USAID: Following the Money". Hearing May 11, 2011. <u>http://oversight.house.gov/hearing/usaid-following-the-money/</u>.

<sup>5</sup> Gallup. "Corruption Tops the List as the World's Most Important Problem According to WIN/Gallup International's Annual Poll." February 2014. <u>http://www.gallup-international.bg/en/Publications/71-Publications/181-Corruption-Tops-the-List-as-the-World%E2%80%99s-Most-Important-Problem-According-to-WIN-Gallup-International%E2%80%99s-Annual-Poll.</u>

<sup>6</sup> Stephenson M. "Yes, Corruption Is Bad for Development. No, Corruption Is Not a Western Obsession." Anticorruption Blog Post, April 29, 2014. <u>http://globalanticorruptionblog.com/2014/04/29/yes-corruption-is-bad-for-development-no-corruption-is-not-a-western-obsession-2/</u>.

<sup>7</sup> Glennie A, Straw W, Wild L (2012). *Understanding Public Attitudes to Aid and Development*. Overseas Development Institute Report. <u>http://www.odi.org/sites/odi.org.uk/files/odi-assets/publications-opinion-files/7708.pdf</u>.

<sup>8</sup> KFF. 2013 Survey of Americans on the U.S. Role in Global Health. <u>http://kff.org/global-health-policy/poll-finding/2013-survey-of-americans-on-the-u-s-role-in-global-health/</u>.

<sup>9</sup> Farmer P (2013). "Rethinking Foreign Aid." *Foreign Affairs* December 12. <u>https://www.foreignaffairs.com/articles/2013-12-12/rethinking-foreign-aid</u>.

<sup>10</sup> Bill & Melinda Gates Foundation (2013). Annual Letter 2013. <u>http://www.gatesfoundation.org/who-we-are/resources-and-media/annual-letters-list/annual-letter-2013</u>.

<sup>11</sup> Transparency International. "FAQs on Corruption". <u>https://www.transparency.org/whoweare/organisation/faqs\_on\_corruption/2/</u>.

<sup>12</sup> UN Office on Drugs and Crime. United Nations Convention Against Corruption. <u>http://www.unodc.org/unodc/en/treaties/CAC/</u>.

<sup>13</sup> Transparency International. Corruption Perceptions Index. <u>http://www.transparency.org/research/cpi/overview</u>.

<sup>14</sup> AfroBarometer. <u>http://www.afrobarometer.org/</u>.

<sup>15</sup> Referenced in Lewis M, Pettersson G. (2009). Governance In Health Care Delivery : Raising Performance. World Bank. <u>http://elibrary.worldbank.org/doi/abs/10.1596/1813-9450-5074</u>.

<sup>16</sup> Office of the Inspector General (OIG), Global Fund Audits can be found here: <u>http://www.theglobalfund.org/en/oig/reports/</u>. The USAID OIG Audit Schedule 2014 is here: <u>http://oig.usaid.gov/sites/default/files/other-reports/fy14\_annual\_plan\_new.pdf</u>. The PEPFAR Coordinated Audit Plan for FY2013 is here: <u>http://oig.usaid.gov/sites/default/files/other-reports/2013</u> coordinated plan.pdf.

<sup>17</sup> McPake et al. Informal Economic Activities of Public Health Workers in Uganda: Implications for Quality and Accessibility of Care. Social Science & Medicine 49 (1999):849-865.

<sup>18</sup> World Bank. 2000. The Ghana Governance and Corruption Survey, Evidence from Households, Enterprises and Public Officials. Referenced in Lewis M (2006). Governance and Corruption in Public Health Care Systems. Center for Global Development Working Paper 78. <u>http://www1.worldbank.org/publicsector/anticorrupt/Corruption%20WP\_78.pdf</u>.

<sup>19</sup> Lewis M, Pettersoson G (2009). Governance in Health Care Delivery: Raising Performance. World Bank Policy Research Working Paper 5074. <u>http://elibrary.worldbank.org/doi/pdf/10.1596/1813-9450-5074</u>.

<sup>20</sup> Pincock S. WHO tries to tackle problem of counterfeit medicines in Asia. *BMJ* 2003;327:1126.

<sup>21</sup> Rivers B. Corruption by Global Fund Grant Implementers. Global Fund Observer (AIDSpan) 139, January 2011. http://www.aidspan.org/gfo\_article/corruption-global-fund-grant-implementers.

<sup>22</sup> Nayyar G, et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infectious Diseases 12(6):488–496, June 2012. : <u>http://dx.doi.org/10.1016/S1473-3099(12)70064-6</u>

<sup>23</sup> Gavi Alliance (2013). GAVI review of health system strengthening in Sierra Leone. April 11. <u>http://www.gavi.org/library/news/statements/2013/gavi-review-of-health-system-strengthening-in-sierra-leone/</u>

<sup>24</sup> Transparency International. Global Corruption Barometer 2013. <u>http://www.transparency.org/gcb2013</u>.

<sup>25</sup> Cross-country ecological studies have found correlations between high levels of perceived corruption at the national level and poorer health indicators such as child mortality, immunization rates, for example: Hanf, M. et al. (2011). Corruption Kills: Estimating the Global Impact of Corruption on Children Deaths. PLoS ONE 6(11): e26990. doi:10.1371/journal.pone.0026990; Witvliet M, et al. Sick regimes and sick people: a multilevel investigation of the population health consequences of perceived national corruption. Tropical Medicine & International Health 18(10):1240–1247, October 2013; and Lin, R.T. et al. (2014). Governance matters: an ecological association between governance and child mortality. Int Health. 6(3):249-57. doi: 10.1093/inthealth/ihu018. Epub 2014. Other studies have found relationships between corruption and poorer health outcomes, such as a study in the Philippines that found that corruption in that country "reduces the immunization rates, delays the vaccination of newborns, discourages the use of public health clinics, reduces satisfaction of households with public health services, and increases waiting time at health clinics": Azfar O, Gurgur T. Does corruption affect health outcomes in the Philippines? *Econ Gov* (2008) 9:197-244, and a study that examined how corruption measures were related to declines in AIDS deaths in sub-Saharan Africa, which concluded: "Countries with higher levels of corruption experience a significantly smaller drop in AIDS deaths as a result of the same quantity of ARVs imported." Friedman W (2015). Corruption and Averting AIDS Deaths. Center for Global Development Working Paper 395, February. <u>http://www.cgdev.org/publication/corruptionand-averting-aids-deaths-working-paper-395</u>.

<sup>26</sup> More information about pay-for-performance and results-based financing and its potential to reduce corruption can be found in: Kenny C, Savedoff W (2013). Can Results-Based Payments Reduce Corruption? Center for Global Development Working Paper 345, September. <u>http://www.cgdev.org/sites/default/files/can-results-based-payments-reduce-corruption.pdf</u>; and Lewis M, Pettersoson G (2009). Governance in Health Care Delivery: Raising Performance. World Bank Policy Research Working Paper 5074. <u>http://elibrary.worldbank.org/doi/pdf/10.1596/1813-9450-5074</u>.

<sup>27</sup> For example a policy to increase wages of health workers to curb absenteeism will likely work better if there are also systems in place that monitor absenteeism rates and impose sanctions.

<sup>28</sup> Vian T, et al (2011). Confronting Corruption in the Health Sector in Vietnam: Patterns and Prospects. Boston University Center for Global Health and Development Discussion Paper 14, October.

<sup>29</sup> Savedoff W (2008). The impact of information and accountability on hospital procurement corruption in Argentina and Bolivia. U4 Anti-corruption Centre Brief, May. <u>http://www.cmi.no/publications/file/3027-the-impact-of-information-and-accountability-on.pdf</u>

<sup>30</sup> Barber S, Bonnet F, Bekedam H. 2004. Formalizing under-the-table payments to control out-of-pocket hospital expenditures in Cambodia. Health Policy and Planning 19:199–208.

<sup>31</sup> Garcia-Prado (2005). Sweetening the Carrot: Motivating public physicians for better performance. World Bank Policy Research Working Paper 3772, November. <u>http://elibrary.worldbank.org/doi/abs/10.1596/1813-9450-3772</u>.

<sup>32</sup> A recent comprehensive review of USAID anti-corruption programs found, just five USAID grants between 2007-2013 focused on anti-corruption or good governance in the health sector – two in the Middle East, two in Eastern Europe, and one in Southeast Asia. The combined budget of these five programs was \$137 million, which amounted to 1.7% of the agency's overall spending on anticorruption in all sectors over this period. Source: Management Sciences International (2014). Analysis of USAID anti-corruption programs (2007-2013).

http://www.usaid.gov/sites/default/files/documents/1866/AnalysisUSAIDAnticorruptionProgrammingWorldwideFinalReport2007-2013.pdf.

<sup>33</sup> For more information, see: Savedoff W (2012). Massive Corruption Revisited: The Value of Portfolio Estimates. Center for Global Development Blog Post, July 24. <u>http://www.cgdev.org/blog/massive-corruption-revisited-value-portfolio-estimates</u>.

<sup>34</sup> USAID <u>Country Operational Plans</u> may contain anti-corruption plans, policies and goals, but not always health-sector specific ones.

<sup>35</sup> More information about pay-for-performance and results-based financing and its potential to reduce corruption can be found in: Kenny C, Savedoff W (2013). Can Results-Based Payments Reduce Corruption? Center for Global Development Working Paper 345, September. <u>http://www.cgdev.org/sites/default/files/can-results-based-payments-reduce-corruption.pdf</u>; and Lewis M, Pettersoson G (2009). Governance in Health Care Delivery: Raising Performance. World Bank Policy Research Working Paper 5074. <u>http://elibrary.worldbank.org/doi/pdf/10.1596/1813-9450-5074</u>.

<sup>36</sup> An estimated 95% of U.S. global health assistance provided by the US Agency for International Development (USAID) for nongovernmental organizations is channeled through U.S.-based NGOs. 5% goes to foreign-based NGOs. See: <u>http://kff.org/global-health-policy/report/ngo-engagement-in-u-s-global-health-efforts-u-s-based-ngos-receiving-usg-support-through-usaid/</u>.

<sup>37</sup> Oxfam America recently published a report examining moving to local ownership as a way to help reduce corruption: Oxfam America (2015). To fight corruption, localize aid. March. <u>http://www.oxfamamerica.org/explore/research-publications/to-fight-corruption-localize-aid/</u>.

<sup>38</sup> KFF. 2012 Survey of Americans on the US Role in Global Health. <u>http://kff.org/global-health-policy/report/2012-survey-of-americans-on-the-u-s-role-in-global-health/</u>.

<sup>39</sup> For example, the Transparency for Development Project will examining impact that transparency and accountability interventions have on public health service delivery is several countries. <u>http://t4dproject.org/</u>.

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400 Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

 $www.kff.org \mid Email \ Alerts: \ kff.org/email \mid facebook.com/KaiserFamilyFoundation \mid twitter.com/KaiserFamFoundation \mid twitter.com/KaiserFa$ 

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.